Federica Pulvirenti1, Cinzia Milito2, Francesco Cinetto3, Ane Fernandez Salinas4, Sara Terreri5, Eva Piano Mortari5, Stefania Auria2, Valentina Soccodato2, Lichtner Miriam6,7, Emanuele Nicastri8, Laura Vincenzi9, Rita Carsetti4, Gianpiero D'Offizi9, Isabella Quinti2. 1. Primary Immune Deficiencies Unit, Azienda Ospedaliera Universitaria Policlinico Umberto I, Rome, Italy. 2. Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy. 3. Department of Medicine-DIMED, University of Padova, and Internal Medicine I, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Treviso, Italy. 4. Department of Molecular Medicine, Sapienza University of Rome and Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. 5. Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. 6. Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy. 7. Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy. 8. National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy. 9. POIT-INMI Spallanzani Infectious Diseases/Hepatology Unit, Rome, Italy.
Abstract
BACKGROUND: Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019. METHODS: We conducted a prospective study on the clinical outcome and antiviral effects of mAbs added to standard of care therapy in SARS-CoV-2-infected patients with primary antibody defects. RESULTS: Median time of SARS-CoV-2 quantitative polymerase chain reaction (qPCR) positivity was shorter in 8 patients treated with mAbs (22 days) than in 10 patients treated with standard of care therapy only (37 days, P=.026). Median time of SARS-CoV-2 qPCR positivity from mAb administration was 10 days. CONCLUSIONS: The SARS-CoV-2 mAbs treatment was effective and well tolerated in patients with primary antibody defects.
BACKGROUND: Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019. METHODS: We conducted a prospective study on the clinical outcome and antiviral effects of mAbs added to standard of care therapy in SARS-CoV-2-infected patients with primary antibody defects. RESULTS: Median time of SARS-CoV-2 quantitative polymerase chain reaction (qPCR) positivity was shorter in 8 patients treated with mAbs (22 days) than in 10 patients treated with standard of care therapy only (37 days, P=.026). Median time of SARS-CoV-2 qPCR positivity from mAb administration was 10 days. CONCLUSIONS: The SARS-CoV-2 mAbs treatment was effective and well tolerated in patients with primary antibody defects.
Authors: Julia Schwaiger; Michael Karbiener; Claudia Aberham; Maria R Farcet; Thomas R Kreil Journal: J Infect Dis Date: 2020-11-13 Impact factor: 5.226
Authors: Karel F A Van Damme; Simon Tavernier; Nele Van Roy; Elisabeth De Leeuw; Jozefien Declercq; Cédric Bosteels; Bastiaan Maes; Marieke De Bruyne; Delfien Bogaert; Victor Bosteels; Levi Hoste; Leslie Naesens; Piet Maes; Alba Grifoni; Daniela Weiskopf; Alessandro Sette; Pieter Depuydt; Eva Van Braeckel; Filomeen Haerynck; Bart N Lambrecht Journal: Front Immunol Date: 2020-11-20 Impact factor: 7.561
Authors: Vincenzo Scaglione; Salvatore Rotundo; Nadia Marascio; Carmela De Marco; Rosaria Lionello; Claudia Veneziano; Lavinia Berardelli; Angela Quirino; Vincenzo Olivadese; Francesca Serapide; Bruno Tassone; Helen Linda Morrone; Chiara Davoli; Valentina La Gamba; Andrea Bruni; Bruno Mario Cesana; Giovanni Matera; Alessandro Russo; Francesco Saverio Costanzo; Giuseppe Viglietto; Enrico Maria Trecarichi; Carlo Torti Journal: BMC Infect Dis Date: 2022-10-20 Impact factor: 3.667
Authors: Cinzia Milito; Francesco Cinetto; Andrea Palladino; Giulia Garzi; Alessandra Punziano; Gianluca Lagnese; Riccardo Scarpa; Marcello Rattazzi; Anna Maria Pesce; Federica Pulvirenti; Giulia Di Napoli; Giuseppe Spadaro; Rita Carsetti; Isabella Quinti Journal: Biomedicines Date: 2022-04-29